Written by: Katie Carter, PharmD, BCPS, Indiana University Health
Olaparib (Lynparza) is a poly ADP-ribose polymerase (PARP) enzyme inhibitor and is currently FDA approved as targeted therapy for BRCA-mutated breast cancer and ovarian cancer. This PQI will highlight its place in therapy in these disease states, safety profiles, and clinical pearls regarding dose adjustment.
Continue reading Olaparib in BRCA-mutated Breast, Ovarian and Pancreatic Cancer
Written by: Martina Fraga, PharmD
This purpose of this PQI is to highlight effective practices to ensure ovarian cancer patients are identified, tested, tracked, and offered a PARP inhibitor when appropriate.
Continue reading Ovarian Cancer: PARP Inhibitor Eligibility
Written by Isabel Houlzet, PharmD, BCPS, BCOP, Miami Cancer Institute
To increase awareness and management of adverse effects related to trifluridine/tipiracil treatment in metastatic colorectal cancer.
Continue reading Trifluridine / Tipiracil for Treatment of Gastric Cancer
Written by: Michelle Hoa and Natasha Heimbigner, PharmD – Summit Cancer Centers
Description of PQI:
Patients undergoing cancer treatment are more susceptible to infections due to their compromised immune system. Proactive steps can be taken before cancer therapy to avoid infections. It is important to know which vaccinations patients can or cannot use, when to use them, and to treat them accordingly so they have the proper protection against preventable infections.
Cancer treatments weaken the immune system rendering it more susceptible to infections.1,2 In order to prevent these infections, cancer patients can either take antimicrobial prophylaxis, get vaccinated, or avoid contact with germs.2 Knowing which vaccinations and when to use them are key to avoid patient harm. Generally, it is best to get vaccinated prior to the start of cancer therapy. Live vaccines should be administered at least four weeks prior to the start of chemotherapy and/or at least 3 months after completion of treatment.1,3 Inactive vaccines should be administered 2 weeks prior to the start of therapy for maximal effect; however, they can be given during therapy. Patients vaccinated during chemotherapy treatment with an inactive vaccine should consider revaccination at least 3 months after therapy as they could be rendered ineffective.3
- Obtain patient vaccination history and reference with CDC recommendations to ensure they are current.
- Determine type of vaccination chemotherapy patient needs.
- Non-replicating (inactive) vaccines: should be given at least 2 weeks before the initiation of chemotherapy or other immunosuppressive therapy to maximize immune response.1
- For a healthy immune system, it typically takes up to 2 weeks after vaccination for the immune system to respond to exposed pathogen. Immunocompromised patients may have reduced or no response to vaccine, which may hinder the effectiveness of immunity for patient. Vaccination, 2 weeks prior to chemotherapy, allows immune systems to build an immune response against the targeted pathogen.
- Antibody response is suboptimal if given vaccination during immunosuppressive therapy but is better than not vaccinating.1
- The immune response to vaccine antigens is not as good as that of an immunocompetent patient; repeat vaccination or boosters may be beneficial in prolonging immunity.4
- Replicating live vaccines: should be given at least 4 weeks prior to and at least 3 months after immunosuppressive therapy.1
- Live vaccinations contain a weak live version of the virus it is intended to vaccinate against; however, an immunocompromised system will not be able to fight against it. The live virus could cause vaccine-derived infections
- An adequate immune response usually occurs 3 to 12 months after the completion of chemotherapy. Patients should wait at least 3 months after the completion of therapy to receive live vaccination.5
- Vaccination should be delayed for at least 6 months after treatment if the patient is receiving anti-B-cell antibodies.2
- Based on chemotherapy regimen
- Guide patients to reference the package insert for all oncolytic specific vaccination suggestions
Patient Centered Activities:
- If patient has not been vaccinated, counsel patient on the importance of vaccination.
- Patients who are immunocompromised are at higher risk for certain diseases; additional vaccines are recommended.4
- Immunocompromised patients recommended to receive TIV and polysaccharide-based vaccines (PCV, PPV, MCV4, MPSV, and Hib vaccines).8
- Do get flu vaccination. Do NOT get nasal mist flu vaccine since it is a live vaccine. Live vaccinations are not recommended for immunocompromised patients.
- Influenza-related hospitalization is 3 to 5 times higher in cancer patients.
- Pneumococcal vaccine (PCV13 and PPV23)
- Immunocompromised children and adults should receive PCV13 and are recommended to receive PPV23 vaccine about 8 weeks later.8 Patients then receive a second dose of PPV23 5 years after the first PPV23.8
- Patients that received at least one dose of PPV23 should receive PCV13 no sooner than 1 year after last PPV23 dose.8
- Help patients with weak immune systems fight off serious lung, blood, or brain bacterial infections.7
- Beneficial for patients with multiple myeloma, lung cancer, chronic lymphocytic leukemia, and lymphoma.1
- Zostavax® vs Shingrix®
- Zostavax® is a live attenuated vaccine whereas Shingrix® is an inactivated recombinant zoster vaccine.
- Zostavax® is contraindicated in immunocompromised patients due to it being a live attenuated vaccine.
- While Shingrix® is not contraindicated in immunocompromised persons, it is not recommended by ACIP at this time due to its lack of research.9
- Counsel patients who are on immunotherapy on vaccination recommendations and precautions.
- Immunotherapy has variable immunomodulatory and immunosuppressive effects. Patients undergoing immunotherapy may or may not experience a suppressed immune response.
- Vaccine may be triggering an exaggerated immune response in certain patients.11
- Recent reports suggest that influenza vaccines given to patients on certain types of immunotherapy triggered an amplified immune-related adverse reaction.10,11
- Some patients receiving immune checkpoint inhibitors experienced an intensified immune response.11
- Consult with prescriber if vaccination is appropriate with current immunotherapy.
- Follow up with patient 3 months after chemotherapy is complete.
- If patient had inactive vaccine during chemotherapy, remind patient to get revaccinated 3 months after treatment.
- If patient is over 65 or has an altered immune system, the CDC recommends a flu vaccine every year and pneumonia vaccine (PPSV23) every 5 years. PCV13 vaccine should only be given once.
- Booster Tdap vaccination should be considered for patients who have completed chemotherapy.1 Tdap booster should also be given every 10 years since last Tdap/Td vaccination.
- Counsel family on receiving live vaccines around patients undergoing chemotherapy.
- Ariza-Heredia, Ella J, and Roy F Chemaly. “Practical Review of Immunizations in Adult Patients with Cancer.” Human Vaccines & Immunotherapeutics 11.11 (2015): 2606–2614.
- Centers for Disease Control and Prevention. Recommendations of the advisory committee on immunization practices (ACIP): Use of vaccines and immune globulins in persons with altered immunocompetence. Morbidity and Mortality Weekly Report. 1993;42(RR-4). Available from: https://dosinghealth.com/wp-content/uploads/2017/09/rr4204.pdf
Vaccination Flow Chart:
Table 1: Types of Vaccines
|Type of Immunization||Principle of Action||Examples||Comments|
|Non-replicating vaccines||Based on toxoid, protein subunits, bacterial, antigens, or immunogenic proteins obtained with recombinant, technology.||Tetanus, diphtheria, pertussis, poliomyelitis, hepatitis B, influenza, varicella zoster (shingles) (Shingrix®), Haemophilus influenza, pneumococcus, meningococcus||Usually requires 3–5 doses; antibody titers diminishes with time|
|Replicating live vaccines||Produced by disabling the virulent properties of a disease-producing virus or bacterium||Measles-mumps-rubella, varicella (chicken pox), varicella zoster (shingles) (Zostavax®) intranasal influenza, yellow fever, oral polio, oral typhoid||Severe reactions are possible; transmission of live pathogen may occur; most provide immunity with 1 dose|
|Passive immunization||Antibodies are infused to provide short-term protection||Varicella Immunoglobulin, hepatitis B immunoglobulin||Protection diminishes after weeks or months|
Written by: Michelle Phillips, PharmD, University of Rochester Medical Center
The purpose of this PQI is to highlight key criteria for appropriate monitoring, dosing, and administration to improve the dispensing and management of patients taking niraparib (Zejula).
Continue reading Niraparib: dose modifications based on weight and platelet counts